Lucas Busch

Dr. Lucas Busch

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Circulation
Verified
Journal Article
Open access
WJWissam A. Jaber
Wissam A. Jaber
CGCarin F. Gonsalves
Carin F. Gonsalves
SSStefan Stortecky
Stefan Stortecky
SHSamuel Horr
Samuel Horr
OPOrestis Pappas
Orestis Pappas
FIfor the PEERLESS Committees and Investigators*
for the PEERLESS Committees and Investigators*
BACKGROUND: There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism. METHODS: PEERLESS is a prospective, multicenter, randomized controlled trial that enrolled 550 patients with intermediate-risk pulmonary embolism with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary end point was a hierarchal win ratio composite of the following (assessed at the sooner of hospital discharge or 7 days after the procedure): (1) all-cause mortality, (2) intracranial hemorrhage, (3) major bleeding, (4) clinical deterioration and/or escalation to bailout, and (5) postprocedural intensive care unit admission and length of stay. Assessments at the 24-hour visit included respiratory rate, modified Medical Research Council dyspnea score, New York Heart Association classification, right ventricle/left ventricle ratio reduction, and right ventricular function. End points through 30 days included total hospital stay, all-cause readmission, and all-cause mortality. RESULTS: The primary end point occurred significantly less frequently with LBMT compared with CDT (win ratio, 5.01 [95% CI, 3.68–6.97]; P <0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% versus 5.4%; P =0.04) with LBMT compared with CDT and less postprocedural intensive care unit use ( P 24 hours (19.3% versus 64.5%). There were no significant differences in mortality, intracranial hemorrhage, or major bleeding between strategies or in a secondary win ratio end point including the first 4 components (win ratio, 1.34 [95% CI, 0.78–2.35]; P =0.30). At the 24-hour visit, respiratory rate was lower for patients treated with LBMT (18.3±3.3 versus 20.1±5.1; P <0.001), and fewer had moderate to severe modified Medical Research Council dyspnea scores (13.5% versus 26.4%; P <0.001), New York Heart Association classifications (16.3% versus 27.4%; P =0.002), and right ventricular dysfunction (42.1% versus 57.9%; P =0.004). Right ventricle/left ventricle ratio reduction was similar (0.32±0.24 versus 0.30±0.26; P =0.55). Patients treated with LBMT had shorter total hospital stays (4.5±2.8 overnights versus 5.3±3.9 overnights; P =0.002) and fewer all-cause readmissions (3.2% versus 7.9%; P =0.03), whereas 30-day mortality was similar (0.4% versus 0.8%; P =0.62). CONCLUSIONS: PEERLESS met its primary end point in favor of LBMT compared with CDT in treatment of intermediate-risk pulmonary embolism. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural intensive care unit use compared with CDT, with no difference in mortality or bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05111613.

1 September 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PMPhilipp Mourikis
Philipp Mourikis
SZSaif Zako
Saif Zako
LDLisa Dannenberg
Lisa Dannenberg
ANAmir M. Nia
Amir M. Nia
YHYvonne Heinen
Yvonne Heinen
APAmin Polzin
Amin Polzin

3 March 2023 in Microvascular Research
Verified
Journal Article
Closed access
JSJ. Schremmer
J. Schremmer
LBLucas Busch
Lucas Busch
SBS. Baasen
S. Baasen
YHY. Heinen
Y. Heinen
RSR. Sansone
R. Sansone
Manuel SternManuel Stern
Manuel Stern

29 November 2015 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
ENEliano Navarese
Eliano Navarese
Michalina KołodziejczakMichalina Kołodziejczak
Michalina Kołodziejczak
DDDimitrios Dimitroulis
Dimitrios Dimitroulis
GWGeorg Wolff
Georg Wolff
LBLucas Busch
Lucas Busch
MCMarco Matteo Ciccone
Marco Matteo Ciccone
Statins are recommended as first-line therapy for patients with hypercholesterolaemia. A sizable proportion of patients, however, does not reach therapeutic goals, is statin intolerant, or, despite optimal statin therapy, is at high risk of ischaemic events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in lipid metabolism and several comorbidities. Monoclonal antibodies targeting PCSK9 are a new lipid-lowering approach with the potential to improve clinical outcomes in patients with dyslipidaemia. In this review, we discuss current experimental and clinical evidence of the role of PCSK9 and its inhibition on lipid metabolism and several pathologic conditions with a focus on clinical outcomes. A state-of-the-art analysis of current clinical evidence and future directions on PCSK9 and its inhibition is provided.

1 December 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
IAIsabel Albers
Isabel Albers
EZErika Zernickel
Erika Zernickel
MSManuel Stern
Manuel Stern
MBMelanie Broja
Melanie Broja
LBLucas Busch
Lucas Busch
CSChristoph Viktor Suschek
Christoph Viktor Suschek

3 April 2020 in Platelets
Verified
Journal Article
Closed access
LBLucas Busch
Lucas Busch
MSManuel Stern
Manuel Stern
LDLisa Dannenberg
Lisa Dannenberg
PMPhilipp Mourikis
Philipp Mourikis
MGMichael Gröne
Michael Gröne
MKMalte Kelm
Malte Kelm
Objective: High on-treatment platelet reactivity (HTPR) to dual antiplatelet therapy (DAPT) predicts adverse events in coronary artery disease patients. In peripheral artery disease (PAD) patients, data concerning the clinical impact of HTPR are limited. Therefore, we evaluated the incidence of (i) HTPR to DAPT and (ii) its impact on 6 months outcome after angioplasty. Methods and results: In this prospective single center analysis, we investigated 102 consecutive patients with PAD from 2016 to 2017. All patients underwent peripheral endovascular treatment due to intermittent claudication (Fontaine IIb). Clopidogrel effects were measured using vasodilator-stimulated protein phosphorylation (VASP) assay, aspirin effects by light-transmission aggregometry (LTA). Major adverse limb events (MALE), major adverse cardiac and cerebrovascular events (MACCE) and BARC bleeding (bleeding academic research consortium classification) within 6 months were assessed. HTPR to clopidogrel (n = 37, 36%), to aspirin (n = 11, 11%) and to both (n = 11, 11%) were frequent. Compared to sufficient platelet inhibition by aspirin and clopidogrel (n = 43, 42%), patients with dual HTPR showed a higher risk of MALE at 6 months (27% vs. 7%; hazard ratio [HR]: 4.45; 95% confidence interval [CI]: 1.1 to 67.8; p = .03). This was independent of diabetes, creatinine, body mass index, and age as well as of procedural details in a multivariate logistic regression analysis. MACCE (n = 2) and BARC bleeding rates (n = 2) were low. Conclusion: In this small exploratory study, HTPR was frequent in PAD patients. Furthermore, the results are suggestive that MALE might be associated with dual HTPR. This leads to the hypothesis that optimized antithrombotic regimens post percutaneous transluminal angioplasty should be tested in clinical trials.